SLC16A13 and metabolic dysfunction-associated steatotic liver disease: Since SLC16A13 transports l-lactate across the plasma membrane, we hypothesize that the transporter causally contributes to the development of NAFLD and insulin resistance through changes in hepatic monocarboxylate transport, affecting cellular energy metabolism, hepatic lipid content, and insulin sensitivity.